Connect with us
Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter's valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement...
Reig Jofre reported a 15% drop in profits in the first quarter of 2024, attributed to the absence of a biosimilar development milestone. However, overall growth...
Boehringer Ingelheim Spain significantly increased its R&D&I investment to 62.7 million euros, up 36% from the previous year, representing 11.5% of net sales. Their human health...
Zolgensma, Novartis' gene therapy for SMA, remains the world's most expensive medicine, priced between $1.2 million and $2.1 million per dose. Despite its high cost, it's...
The pharmaceutical industry sees a surge in R&D investment, reaching $145.5 billion last year, 4.5% higher than drug launch budgets in 2022. Deloitte's report on pharmaceutical...
Novo Nordisk sees substantial growth, reporting a 28% increase in profits to €3.4 billion in Q1 2024, with operating profits up 27% to €4.27 billion. This...
Berenberg has slashed Grifols' target price by 23% to 19.8 euros due to higher-than-expected net debt. Despite this, Berenberg remains optimistic about Grifols' potential, estimating a...
Eli Lilly's first-quarter results exceeded expectations, with a $8.77 billion turnover, a 26% year-on-year growth, and $2.24 billion net income, 67% higher than in 2023. Strong...
Laminar Pharma, founded by Professor Pablo Vicente Escribá, seeks to raise €7 million for its drug trial, LAM561, targeting glioblastoma. With phase III trials underway in...
Bioprinting, once hailed for its potential to print human organs and tissues, took a backseat after the pandemic. However, with an estimated market value of $1.44...
 |
|
 |  |
 |
|